NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Gene Synthesis Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 824084
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
遺傳基因合成的全球市場:成長,趨勢,預測(2019∼2024年) Gene Synthesis Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 110 Pages



第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 推動市場的要素
    • 基因學和次世代定序的領域的研究開發擴大
    • 政府對基因學的資金援助
    • 對個人化醫療的需求擴大
  • 阻礙市場的要素
    • 熟練的專家不足
    • 成本高及技術的複雜
  • 波特五力分析

第5章 市場區隔

  • 各手法
    • 寡核苷酸合成
    • 遺傳基因集合
  • 各終端用戶
    • 學術研究機關
    • 生物醫藥品廠商
    • CRO
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭趨勢

  • 企業簡介
    • ATUM (DNA2.0 Inc.)
    • Bio Basic Inc.
    • Beijing SBS Genetech Co. Ltd
    • Eurofins Genomics
    • Genewiz Inc.
    • Genscript Biotech Corp.
    • Merck KGaA
    • OriGene Technologies Inc.
    • Thermo Fisher Scientific Inc. (GeneArt)

第7章 市場機會與未來趨勢


Product Code: 64485

Factors that are responsible for the growth of Gene Synthesis market include increasing R&D in the field of genomics and next-generation sequencing, increased government funding toward genomics, and increasing demand for personalized medicine. As personalized medicine aims to provide tailor-made therapies to individual patients, depending on the molecular basis of disease, it has become popular over recent years. Healthcare technology, genomics, connected devices, big data analytics, and artificial intelligence are generating vast amounts of health data and insights. This is enabling healthcare providers to offer better and faster diagnoses, and make more informed treatment decisions. Factors, such as the aging global population and rising prevalence of chronic diseases, are putting unrelenting pressure on the capacity and financial viability of the healthcare systems across the world. Personalized medicine holds the promise of providing better patient care and a high safety margin, while lowering the total healthcare costs. In addition, gene synthesis is also finding its applications in the molecular diagnosis of infectious and genetic diseases. Genetic tests, which can detect genetic variations and predict how a person is likely to respond to certain drugs, are becoming commercially available.

Therefore, increasing focus on personalized medicine and other factors, such as patient-centered approach, are driving the growth of the gene synthesis market.

Key Market Trends

PCR-mediated Assembly is Expected to Grow Rapidly in the Gene Assembly Segment

In the gene synthesis process, the chemical synthesis is typically used to create oligonucleotides of up to 120-150 nucleotide (nt) in length. Therefore, generally, gene assembly techniques are utilized to connect small oligonucleotides with each other, to synthesize the gene of the required length. Over the past three decades, a number of methods have been developed to assemble relatively short synthetic oligonucleotides into longer gene sequences. And the PCR-mediated assembly represents one of the most prominent approaches to mediate assembly of the desired DNA sequence. Pertaining to the broad applications of PCR, such as in molecular diagnostics, forensics, and epidemiology studies, the demand and acceptance of PCR technologies are high, which, in turn, acts as a favorable factor for the development and adoption of PCR-mediated assembly methodologies, by academia and research institutes alike.

North America Dominates the Market and is Expected to do Same during the Forecast Period

Currently, North America dominates the market for gene synthesis, and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. The increasing prevalence of genetic and chronic disorders, such as cancer, aging population, increasing demand for targeted and personalized medicine, and favorable government initiatives are the primary factors responsible for the large market.

Competitive Landscape

The gene synthesis market is moderately competitive and consists of several major players. In terms of the market share, few of the major players currently dominate the market. Owing to the increasing number of diseases and rising drug discovery processes, few other smaller players are expected to enter the market. Some of the major players of the market are Merck KGaA, Genscript Biotech Corp., Genewiz Inc., Eurofins Genomics, and Bio Basic Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing R&D in the Field of Genomics and Next Generation Sequencing
    • 4.2.2 Increased Government Funding toward Genomics
    • 4.2.3 Increasing Demand for Personalized Medicine
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Professionals
    • 4.3.2 High Cost and Complexity of Techniques
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Method
    • 5.1.1 Oligonucleotide Synthesis
      • Solid Phase Phosphoramidite Synthesis
      • Microchip-based Oligonucleotide Synthesis
    • 5.1.2 Gene Assembly
      • Ligation-mediated Assembly
      • PCR-mediated Assembly
  • 5.2 By End User
    • 5.2.1 Academic and Research Institutes
    • 5.2.2 Biopharmaceutical Companies
    • 5.2.3 Contract Research Organizations
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 ATUM (DNA2.0 Inc.)
    • 6.1.2 Bio Basic Inc.
    • 6.1.3 Beijing SBS Genetech Co. Ltd
    • 6.1.4 Eurofins Genomics
    • 6.1.5 Genewiz Inc.
    • 6.1.6 Genscript Biotech Corp.
    • 6.1.7 Merck KGaA
    • 6.1.8 OriGene Technologies Inc.
    • 6.1.9 Thermo Fisher Scientific Inc. (GeneArt)